Sonoma Pharmaceuticals, Inc. (SNOA)
2025-03-31 | ||||
|---|---|---|---|---|
| Revenues | 14,288 | |||
| Cost of revenues | 8,823 | |||
| Gross profit | 5,465 | |||
| Selling, general and administrative | 7,361 | |||
| Research and development | 1,814 | |||
| Total operating expenses | 9,175 | |||
| Loss from operations | -3,710 | |||
| Other income (expense), net | 803 | |||
| Loss from operations before income taxes | -2,907 | |||
| Income tax (expense) benefit | 550 | |||
| Net loss | -3,457 | |||
| Foreign currency translation adjustments | -1,653 | |||
| Comprehensive loss | -5,110 | |||
| Net loss per share basic | -2.79 | |||
| Net loss per share diluted | -2.79 | |||
| Weighted-average number of shares basic | 1,241,000 | |||
| Weighted-average number of shares diluted | 1,241,000 | |||